You are here: Industry Insights > Gimoti

News List

Evoke, EVERSANA Announce Commercial Launch of Gimoti™ americanpharmaceuticalreview
October 30, 2020
Evoke Pharma and EVERSANA™ have announced the commercial launch of Gimoti™ (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Patheon to Manufacture FDA-Approved Nasal Spray contractpharma
July 20, 2020
Evoke Pharma initiates commercial manufacturing of Gimoti with the CDMO.
Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti NDA drugs
April 03, 2019
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food ...
FDA rejects approval of Evoke Pharma's Gimoti for diabetic gastroparesis firstwordpharma
April 02, 2019
Evoke Pharma announced Tuesday that the FDA issued a complete response letter regarding a filing under the 505(b)(2) pathway……